Closed-loop device uses light to control overactive bladder
Researchers developed this small device implanted around the bladder of a rat to provide closed-loop bladder control. It uses light signals from tiny LEDs to activate nerve cells in the bladder. (Image courtesy of Gereau Lab, Washington University)
A team of neuroscientists and engineers has developed a tiny, implantable, closed-loop device that may replace medication or electronic stimulators for bladder disorders.
The team from Washington University School of Medicine in St. Louis, the University of Illinois at Urbana-Champaign, and the Feinberg School of Medicine at Northwestern University in Chicago created a soft, imp...
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Neuromodulation/Neurostimulation News Well Research & Development Urology feinbergschoolofmedicineatnorthwesternuniversity University of Illinois at Urbana-Champaign Washington University School of Medicine Source Type: news
Risk of 4 Pelvic Floor Disorders Associated With Delivery Mode (CME/CE)
(MedPage Today) -- Lower risk of stress urinary incontinence, overactive bladder, and pelvic organ prolapse with cesarean delivery than with surgical and non-surgical vaginal births (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 23, 2018 Category: OBGYN Source Type: news
Incontinence Drug May Help Ease Severe Hot Flashes
Oxybutynin, a drug widely used to treat urinary incontinence caused by an overactive bladder, helps treat hot flashes in breast cancer survivors and women who did not have breast cancer but who were bothered by frequent or severe menopausal symptoms, new research shows. (Source: WebMD Health)
Source: WebMD Health - December 17, 2018 Category: Consumer Health News Source Type: news
FDA Approves Smart Programmer for Medtronic Neuromodulation System
FDA approved a new smart programmer for Medtronic's InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI), and non-obstructive urinary retention.
The new programmer streamlines multiple devices into a single, intuitive, touchscreen Samsung mobile device and enables clinicians to personalize each patient's care and allows patients to manage their therapy simply and discreetly, Medtronic said.
According to the company, more than 37 million adults in the United States (almost one in six) suffer from OAB and nearly 20 million Americans (ab...
Source: MDDI - December 17, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Medtronic wins FDA nod for InterStim sacral neuromod programmer
Medtronic (NYSE:MDT) said today that the FDA approved its InterStim smart programmer, designed to work with the company’s InterStim sacral neurmodulation system intended for tor treating overactive bladder, chronic fecal incontinence and non-obstructive urinary retention.
The newly cleared smart programmer is run on a Samsung Electronics (LON:BC94) mobile device and allows clinicians to personalize patient care and manage therapy from a single access point, the Fridley, Minn.-based medical giant said.
“The incorporation of consumer technology in medical device solutions, such as the InterStim system, is not ...
Source: Mass Device - December 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Medtronic samsung Source Type: news
Implantable Device May Relieve Urinary Urge Incontinence in OAB Implantable Device May Relieve Urinary Urge Incontinence in OAB
A small, nickel-sized, battery-powered implant (eCoin) appears to relieve urinary urge incontinence (UUI) associated with overactive bladder (OAB) syndrome by stimulating the tibial nerve, according to a new single-arm trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Axonics adds $18m to $120m IPO
Axonics Modulation Technologies (NSDQ:AXNX) said today that the underwriters behinds its $120 million initial public offering exercised their over-allotment option, adding another $18 million to its coffers.
Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, said the underwriters picked up 1.2 million shares at $15 each, taking gross proceeds from the flotation to $138 million.
Axonics closed the IPO Nov. 2, after first setting a range of $93.3 million to $106.7 million which it later increased to $120 mi...
Source: Mass Device - November 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
Valencia Techs updates on eCoin OAB trials
Valencia Technologies this week updated on the pivotal trial of its eCoin overactive bladder neurostim device, saying it has enrolled more than 35 patients and that it expects to finish implantations by January next year, with a hopeful completion date of January 2020.
The system, which is approximately the size of a nickel, is designed to implanted in a 10 minute procedure and send electrical impulses to the tibial nerve to stimulate the part of the brain that controls bladder response, the New York-based company said.
The single-arm pivotal trial, which won approval by the FDA in March, aims to enroll a total of 120 pat...
Source: Mass Device - November 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Urology Valencia Technologies Source Type: news
Medibio names medical-device veteran Kaysen CEO
Medibio Ltd., which develops technology that aims to diagnose mental-health conditions, has named medical-device industry veteran David Kaysen its CEO and managing director.
Kaysen was most recently CEO of a Sun BioPharma Inc., a biotech company developing drugs to treat diseases affecting the pancreas. He was previously the top executive at medical-device maker Uroplasty Inc., which makes devices that treated overactive bladder and incontinence. (He's also the father of renowned Minneapolis chef… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 2, 2018 Category: Pharmaceuticals Authors: Katharine Grayson Source Type: news
Axonics closes $120m IPO
Axonics Modulation Technologies (NSDQ:AXNX) today closed its $120 million initial public offering, saying it could reap still more from the flotation if an underwriters option is exercised.
Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, had set the range for the flotation at $93.3 million to $106.7 million, but later increased the number of shares to 8 million, priced at $15 each.
The 30-day, 1.2-million-share over-allotment, if fully exercised, would add $18 million to the IPO’s gross.
Axonics t...
Source: Mass Device - November 2, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
Axonics prices upsized $120m offering
Axonics Modulation Technologies yesterday priced an upsized initial public offering that could fetch a maximum of $138 million.
Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, last week set the range for the flotation at $93.3 million to $106.7 million, saying it would issue nearly 6.7 million shares at $14 to $16 apiece.
Yesterday the company increased the number of shares to 8 million, priced at $15 each, for gross proceeds of $120 million. If a 30-day, 1.2-million-share over-allotment is fully exerci...
Source: Mass Device - October 31, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) MassDevice Earnings Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
Axonics sets range for $100m IPO
Axonics Modulation Technologies yesterday set the range on an initial public offering that would fetch $100 million at the midpoint.
The Irvine, Calif.-based company makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. Axonics touts it as the first such rechargeable device; it’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks.
Axonics said it plans to float nearly 6.7 million shares at $14 to $16 apiece, for a gross proceeds range of...
Source: Mass Device - October 23, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
How do pelvic floor muscle exercises reduce overactive bladder symptoms?
(Wolters Kluwer Health) Overactive bladder (OAB) is a common form of urinary incontinence that is widely treated with pelvic floor muscle (PFM) training. A new laboratory study lends insights into how PFM training works: by reducing contractions of the detrusor muscle of the bladder, reports the American Journal of Physical Medicine& Rehabilitation, the official journal of the?Association of Academic Physiatrists. The journal is published by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 19, 2018 Category: International Medicine & Public Health Source Type: news
Velicept raises another $15M to advance overactive bladder treatment
Velicept Therapeutics said Tuesday it raised an additional $15 million through an expansion of its series B financing.
The Malvern pharmaceutical company plans to use the funding to support the completion of two mid-stage clinical trials of its lead new drug candidate Solabegron, which it is developing as a treatment for people with overactive bladders.
Dr. James Walker, president and CEO of Velicept, said the fu nding will also enable the company to prepare for phase-III clinical studies — the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 17, 2018 Category: Biotechnology Authors: John George Source Type: news
Axonics Modulation files for $86m IPO
Axonics Modulation Technologies last week registered for an initial public offering worth more than $86 million for its neuromodulation system for treating urinary and bowel conditions.
The Irvine, Calif.-based company touts its r-SNM device as the first rechargeable sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. It’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks.
Th r-SNM device won CE Mark approval in the European Union in June 2016; an extern...
Source: Mass Device - October 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Initial Public Offering (IPO) Neuromodulation/Neurostimulation Wall Street Beat Axonics Modulation Technologies Source Type: news
